Karthikeyan Adhimoolam, Young Kim Na, Moniruzzaman Mohammad, Beyene Anteneh Marelign, Do Kyoungtag, Kalaiselvi Senthil, Min Taesun
Subtropical Horticulture Research Institute, Jeju National University, Jeju 63243, Korea.
Department of Animal Biotechnology, Jeju International Animal Research Center (JIA) and Sustainable Agriculture Research Institute (SARI), Jeju National University, Jeju 63243, Korea.
Pharmaceutics. 2021 Apr 2;13(4):484. doi: 10.3390/pharmaceutics13040484.
Inflammatory bowel disease (IBD) is a chronic relapsing and remitting inflammatory disorder of the small intestine and colon. IBD includes ulcerative colitis (UC) and Crohn's disease (CD), and it is a major factor for the development of colon cancer, referred to as colitis-associated cancer (CAC). The current treatment of IBD mainly includes the use of synthetic drugs and monoclonal antibodies. However, these drugs have side effects over long-term use, and the high relapse rate restricts their application. In the recent past, many studies had witnessed a surge in applying plant-derived products to manage various diseases, including IBD. Curcumin is a bioactive component derived from a rhizome of turmeric (). Numerous in vitro and in vivo studies show that curcumin may interact with many cellular targets (NF-κB, JAKs/STATs, MAPKs, TNF-γ, IL-6, PPARγ, and TRPV1) and effectively reduce the progression of IBD with promising results. Thus, curcumin is a potential therapeutic agent for patients with IBD once it significantly decreases clinical relapse in patients with quiescent IBD. This review aims to summarize recent advances and provide a comprehensive picture of curcumin's effectiveness in IBD and offer our view on future research on curcumin in IBD treatment.
炎症性肠病（IBD）是一种发生于小肠和结肠的慢性复发性炎症性疾病。IBD包括溃疡性结肠炎（UC）和克罗恩病（CD），并且它是结肠癌（称为结肠炎相关癌，CAC）发生的一个主要因素。IBD的当前治疗主要包括使用合成药物和单克隆抗体。然而，这些药物长期使用有副作用，且高复发率限制了它们的应用。最近，许多研究见证了植物源产品在管理包括IBD在内的各种疾病方面的应用激增。姜黄素是一种从姜黄根茎中提取的生物活性成分。大量体外和体内研究表明，姜黄素可能与许多细胞靶点（NF-κB、JAKs/STATs、MAPKs、TNF-γ、IL-6、PPARγ和TRPV1）相互作用，并有效减缓IBD的进展，结果令人满意。因此，一旦姜黄素能显著降低静止期IBD患者的临床复发率，它将成为IBD患者的一种潜在治疗药物。本综述旨在总结近期进展，并全面介绍姜黄素在IBD中的有效性，同时就姜黄素在IBD治疗方面的未来研究提出我们的观点。
